Abstract:Background Olaparib combined with paclitaxel has previously shown a significant improvement in overall survival versus placebo plus paclitaxel as second-line therapy in a phase 2 study in Asian patients with advanced gastric cancer, especially in those with ataxia-telangiectasia mutated protein (ATM)-negative tumours. Here, we report the primary efficacy and safety analyses from a subsequent phase 3 trial. Methods This double-blind, randomised, placebo-controlled, phase 3 study (GOLD) recruited Asian patients aged 18 years or older (>= 20 years if Japanese) with advanced gastric cancer that had progressed following, or during, first-line chemotherapy. Patients were randomly assigned (1:1) to receive oral olaparib (100 mg twice daily) plus paclitaxel (80 mg/m(2) intravenously) or matching placebo plus paclitaxel. Randomisation was done through an interactive voice response system and no stratification factors were used. Patients and investigators were masked to treatment allocation. Two co-primary populations were assessed: the overall population of all patients and patients whose tumours were ATM-negative (identified after randomisation, before the data cutoff date, March 28, 2016). The primary endpoint in both populations was overall survival (defined as the time from the date of randomisation until death from any cause before data cutoff); a significant difference was defined as p<0.025. Efficacy was assessed in the intention-to-treat populations and safety in patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, number NCT01924533 (study ID, D081BC00004), and is ongoing but no longer recruiting participants. Findings Between Sept 3, 2013, and March 28, 2016, 643 patients were enrolled from 58 study sites in hospitals and medical centres in China, Japan, South Korea, and Taiwan. 525 eligible patients were randomly assigned: 263 to receive olaparib plus paclitaxel and 262 to receive placebo plus paclitaxel. 94 patients were determined to have ATM-negative tumours before unmasking for the primary analysis (48 in the olaparib plus paclitaxel group and 46 in the placebo plus paclitaxel group). Overall survival did not differ between treatment groups in the overall patient population (median overall survival 8.8 months [95% CI 7.4-9.6] in the olaparib group vs 6.9 months [6.3-7.9] in the placebo group; HR 0.79 [97.5% CI 0.63-1.00]; p=0.026) or in the ATM-negative population (12.0 months [7.8-18.1] vs 10.0 months [6.4-13.3]; 0.73 [0.40-1.34]; p=0.25). In the overall patient population, the most common grade 3 or worse adverse events in the olaparib plus paclitaxel group were neutropenia (78 [30%] of 262 patients), leucopenia (42 [16%]), and decreased neutrophil count (40 [15%]); in the placebo plus paclitaxel group, they were neutropenia (59 [23%] of 259 patients), leucopenia (27 [10%]), and decreased white blood cell count (21 [8%]). Adverse events with an outcome of death causally related to study treatment (according to investigator assessment) were reported in two patients: liver injury in one patient (<1%) in the olaparib plus paclitaxel group and cardiac failure in one patient (<1%) in the placebo plus paclitaxel group. Interpretation The GOLD study did not meet its primary objective of showing a significant improvement in overall survival with olaparib in the overall or ATM-negative population of Asian patients with advanced gastric cancer. The study generated informative efficacy and safety data regarding the use of olaparib in combination with a chemotherapeutic agent and provides a foundation for future studies in this difficult-to-treat patient population.

Efficacy and Safety of Olaparib in Advanced Ovarian Cancer: a Meta-Analysis

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer

Researoh Progress of Olaparib as Targeted Therapeutics for Advanced Ovarian Cancer

Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China

Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer

Overall Survival (OS) in Patients with Platinum-Sensitive Relapsed Ovarian Cancer (PSROC) Treated with Olaparib Maintenance Monotherapy: Update from the L-MOCA Trial.

Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study

Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials

Pharmacokinetics and Safety of Olaparib Tablets As Monotherapy and in Combination with Paclitaxel: Results of a Phase I Study in Chinese Patients with Advanced Solid Tumours

Olaparib in Combination with Paclitaxel in Patients with Advanced Gastric Cancer Who Have Progressed Following First-Line Therapy (GOLD): a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial.

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

Olaparib-associated toxicity in cancer patients: a systematic review and meta-analysis

Olaparib Maintenance Therapy in Patients (pts) with a BRCA1 And/or BRCA2 Mutation (brcam) and Newly Diagnosed Advanced Ovarian Cancer (OC): SOLO1 China Cohort

Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials

Patient-reported Outcomes in Patients with a Germline BRCA Mutation and HER2-negative Metastatic Breast Cancer Receiving Olaparib Versus Chemotherapy in the OlympiAD Trial.

Efficacy and Safety of PARP Inhibitors in the Treatment of Advanced Ovarian Cancer: an Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Olaparib Maintenance Monotherapy in Chinese Patients with Platinum‐sensitive Relapsed Ovarian Cancer: China Cohort from the Phase III SOLO2 Trial

PARP Inhibitor Treatment of Advanced Breast Cancer Beyond the BRCA-mutated Type: a Meta-Analysis.

Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta‐analysis

Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.